These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22204739)

  • 21. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
    Müller CE; Geis U; Grahner B; Lanzner W; Eger K
    J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies.
    Catarzi D; Colotta V; Varano F; Poli D; Squarcialupi L; Filacchioni G; Varani K; Vincenzi F; Borea PA; Dal Ben D; Lambertucci C; Cristalli G
    Bioorg Med Chem; 2013 Jan; 21(1):283-94. PubMed ID: 23171656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of simplified N²-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies.
    Venkatesan G; Paira P; Cheong SL; Vamsikrishna K; Federico S; Klotz KN; Spalluto G; Pastorin G
    Bioorg Med Chem; 2014 Mar; 22(5):1751-65. PubMed ID: 24518296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives.
    Federico S; Redenti S; Sturlese M; Ciancetta A; Kachler S; Klotz KN; Cacciari B; Moro S; Spalluto G
    PLoS One; 2015; 10(12):e0143504. PubMed ID: 26625265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
    Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
    J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes?
    Baraldi PG; Cacciari B; Borean PA; Varanin K; Pastorin G; Da Ros T; Tabrizi MA; Fruttarolo F; Spalluto G
    Curr Pharm Des; 2002; 8(26):2299-332. PubMed ID: 12369947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new series of 2-alkoxy(aralkoxy)-[1,2,4]triazolo[1,5-a]quinazolin-5-ones as adenosine receptor antagonists.
    Al-Salahi R; Geffken D; Koellner M
    Chem Pharm Bull (Tokyo); 2011; 59(6):730-3. PubMed ID: 21628909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.
    Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Monopoli A; Ongini E; Varani K; Borea PA
    J Med Chem; 2002 Jan; 45(1):115-26. PubMed ID: 11754583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A
    Falsini M; Squarcialupi L; Catarzi D; Varano F; Betti M; Dal Ben D; Marucci G; Buccioni M; Volpini R; De Vita T; Cavalli A; Colotta V
    J Med Chem; 2017 Jul; 60(13):5772-5790. PubMed ID: 28590753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New strategies for the synthesis of A3 adenosine receptor antagonists.
    Baraldi PG; Bovero A; Fruttarolo F; Romagnoli R; Tabrizi MA; Preti D; Varani K; Borea PA; Moorman AR
    Bioorg Med Chem; 2003 Sep; 11(19):4161-9. PubMed ID: 12951147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists.
    Baraldi PG; Cacciari B; Moro S; Spalluto G; Pastorin G; Da Ros T; Klotz KN; Varani K; Gessi S; Borea PA
    J Med Chem; 2002 Feb; 45(4):770-80. PubMed ID: 11831890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.
    Venkatesan G; Paira P; Cheong SL; Federico S; Klotz KN; Spalluto G; Pastorin G
    Eur J Med Chem; 2015 Mar; 92():784-98. PubMed ID: 25633494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
    Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.
    Squarcialupi L; Falsini M; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Dal Ben D; Lambertucci C; Volpini R; Colotta V
    Bioorg Med Chem; 2016 Jun; 24(12):2794-808. PubMed ID: 27161878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.
    Harris JM; Neustadt BR; Zhang H; Lachowicz J; Cohen-Williams M; Varty G; Hao J; Stamford AW
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2497-501. PubMed ID: 21398125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
    J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of novel pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives: potent and selective adenosine A3 receptor antagonists.
    Banda V; Chandrasekaran B; Köse M; Vielmuth C; Müller CE; Chavva K; Gautham SK; Pillalamarri S; Mylavaram R; Akkinepally R; Pamulaparthy S; Banda N
    Arch Pharm (Weinheim); 2013 Oct; 346(10):699-707. PubMed ID: 23996524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of strong intramolecular N-H...N hydrogen bonds in determining the conformation of adenosine-receptor antagonists.
    Ferretti V; Pretto L; Tabrizi MA; Gilli P
    Acta Crystallogr B; 2006 Aug; 62(Pt 4):634-41. PubMed ID: 16840813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
    Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.